Table 1.

Characteristics of patients and administered T cells

Within CD3+ (%)Response
PatientAge (years)/genderHistologyHPV typeSites of diseasePrior systemic treatmentCells (×109)CD4+CD8+No. of IL2 dosesTypeDuration or TTP (months)
Cervical cancer
 130/FASC18Iliac lymph nodes, lung, lung hilum, retroperitoneum, vaginal cuffCisplatin101.429727PD1
 253/FSCC18Bone, liver, lung, lung hilum, mediastinum, pelvisCisplatin, carboplatin, paclitaxel, topotecan, ixabepilone, dimethane sulfonate126.010903PR3
 336/FSCC16Iliac lymph nodes, lung hilum, mediastinum, retroperitoneumCisplatin, vincristine, bleomycin, gemcitabine, paclitaxel, topotecan152.021832CR67+
 455/FSCC16Axilla, breast, liver, omentum, pleura, soft tissueCisplatin, carboplatin, paclitaxel, fluorouracil, irinotecan, dovitinib, pemetrexed80.123767PD2
 544/FSCC18Brain, mediastinum, supraclavicular nodesCisplatin90.066295PD2
 636/FAC18Abdominal wall, liver surface, paracolic, pelvis, retroperitoneumCisplatin74.714868CR53+
 759/FAC18Abdominal wall, lungCisplatin, paclitaxel, carboplatin, bevacizumab33.436588PD1
 831/FASC18Pelvis, perihepatic massCisplatin, paclitaxel46.164299PD2
 937/FAC18Axilla, bone, lung, mediastinum, pelvis, retroperitoneumCisplatin, carboplatin, paclitaxel, ipilimumab70.233596PD1
 1039/FSCCnot 16/18Adrenal, retroperitoneumCisplatin, paclitaxel, bevacizumab100.08925PD2
 1131/FSCC16Cervix, iliac lymph nodes, retroperitoneumCarboplatin, paclitaxel, bevacizumab77.057411PD2
 1248/FSCC16Bone, inguinal lymph nodes, lung, mediastinum, retroperitoneumCisplatin, paclitaxel, bevacizumab, listeria-based vaccine trial70.69340PR3
 1330/FSCC18Cervix, inguinal lymph nodes, lung, mediastinumCisplatin, brachytherapy101.367273PD3
 1449/FSCCnot 16/18Gastro-esophageal junction, mediastinum, retroperitoneumCisplatin, carboplatin, paclitaxel, topotecan, bevacizumab68.853412PD2
 1561/FAC16Bone, inguinal lymph nodes, lungCarboplatin, docetaxel, cisplatin, topotecan, ifosfamide, adriamycin, etoposide73.984161PD3
 1651/FSCC18Liver, pelvic, peripancreatic, spleenCisplatin, gemcitabine, carboplatin, paclitaxel, bevacizumab11571290PD2
 1763/FSCC18Lung, lung hilumCisplatin, carboplatin, paclitaxel, bevacizumab112.078224PD5
 1835/FNE18Lung, lung hilum, liverCisplatin, etoposide, topotecan, paclitaxel, bevacizumab9.067343PR3
Noncervical cancer
 1955/MTonsillar SCC16Axilla, lung, subcutaneous tissueCisplatin, fluorouracil, taxotere, carboplatin, cetuximab89.19621PD2
 2060/MHead/neck SCC16Axilla, bone, liver, peripancreatic, periportal lymph node, pleuraCisplatin, capecitabine, carboplatin150.029646PD2
 2158/FAnal SCC16Lung, mediastinum, pleuraCisplatin, fluorouracil, carboplatin, paclitaxel, cetuximab, irinotecan31.547502PD3
 2250/FAnal SCC16Mediastinum, retroperitoneumCisplatin, fluorouracil, mitomycin C, paclitaxel, carboplatin69.075165PD8
 2358/FAnal SCC16Iliac lymph nodes, liver, retroperitoneumCisplatin, fluorouracil, mitomycin C47.58691PD2
 2460/MTonsillar SCC16Lung, mediastinumCisplatin, docetaxel, bevacizumab, cetuximab, fluorouracil, gemcitabine130.941513PR5
 2549/FAnal SCC16PleuraCisplatin, fluorouracil, rigosertib, capecitabine133.067205PD2
 2648/FAnal SCC16LungCisplatin, fluorouracil, mitomycin C, capecitabine18.447505PR4
 2752/MHead/neck SCC16Axilla, chest wall, lung hilum, mediastinum, subcutaneous tissueCisplatin, fluorouracil, taxotere125.09735PD2
 2860/MHead/neck SCC16Lung, lung hilum, mediastinum, para-aortic lymph node, pleuraCisplatin, carboplatin, fluorouracil, cetuximab, pembrolizumab102.06944PD3
 2956/FVaginal AC16Lung, lung hilum, scapula, para-spinalCisplatin, paclitaxel, carboplatin, pemetrexed107.046555PD4
  • Abbreviations: AC, adenocarcinoma; ASC, adenosquamous cell carcinoma; F, female; M, male; NE, neuroendocrine; SCC, squamous cell carcinoma; TTP, time to progression.